Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

Eli Lilly benefits from rising cash flow and a strong pipeline, yet elevated pricing versus peers limits near-term gains. See ...

Eli Lilly (NYSE:LLY) underwent analysis by 7 analysts ... and Humulin for cardiometabolic; and Taltz and Olumiant for immunology. Market Capitalization: Positioned above industry average, the ...

Eli Lilly has struck a $2.4 billion deal to buy ... like Novartis’ multibillion-dollar blockbuster Cosentyx (secukinumab), Lilly’s Taltz (ixekizumab), Bausch Health/Ortho’s Siliq (brodalumab ...

Cosentyx has since been joined by other IL-17 inhibitors including Eli Lilly's Taltz (ixekizumab) and Bausch Health's Siliq/Kyntheum (brodalumab), but UCB is convinced it can make headway in the ...

The results bring Eli Lilly's pill orforglipron one step closer to becoming a new, needle-free alternative in the booming ...

Eli Lilly and Company traded as low as $718.81 and last traded at $718.89. Approximately 663,002 shares changed hands during trading, a decline of 80% from the average daily volume of 3,354,701 ...

ATLANTA, April 11, 2025 /PRNewswire/ -- On April 01, 2025, OrderlyMeds received a Cease-and-Desist letter from Eli Lilly regarding the compounding of Tirzepatide. This is our open response.

Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...